Synakis is developing novel biomaterial-based treatments for ocular conditions. Created in https://BioRender.com.
Synakis is a pre-clinical biotech startup developing novel biomaterial-based treatments for ocular injuries and diseases, including retinal detachment and glaucoma. Our mission is to restore vision and improve the lives of patients suffering from these conditions.
Synakis’ core technology, SNK-125, is a novel hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous substitute for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Upcoming Events
Want to meet our team and learn more about Synakis? Meet us at these upcoming events:
Ophthalmic Drug Delivery Summit - January 27-29, 2026, San Francisco, CA
Glaucoma 360 - January 30-31, 2026, San Francisco, CA
OBIO Investment Summit - February 3-5, 2026, Toronto, ON
Synakis CEO Thierry Nivaggioli (left) engages community at the Ophthalmic Drug Delivery Summit in San Francisco, CA.
Synakis CEO Thierry Nivaggioli Presents at Ophthalmic Drug Delivery Summit
January 28, 2026
The summit brings together experts in the field to discuss the future of ophthalmic therapies.